300702 天宇股份
等待开盘 11-15 09:30:00
资讯
新帖
简况
天宇股份:10月29日接受机构调研,上海银叶投资有限公司、永赢基金管理有限公司等多家机构参与
证券之星 · 10-30
天宇股份:10月29日接受机构调研,上海银叶投资有限公司、永赢基金管理有限公司等多家机构参与
图解天宇股份三季报:第三季度单季净利润同比增4570.27%
证券之星 · 10-29
图解天宇股份三季报:第三季度单季净利润同比增4570.27%
天宇股份(300702)股东林洁质押160万股,占总股本0.46%
证券之星 · 10-25
天宇股份(300702)股东林洁质押160万股,占总股本0.46%
天宇股份(300702.SZ):奥特康唑原料药通过CDE审评
智通财经 · 10-25
天宇股份(300702.SZ):奥特康唑原料药通过CDE审评
10月8日天宇股份涨9.09%,国泰金鹿混合基金重仓该股
证券之星 · 10-08
10月8日天宇股份涨9.09%,国泰金鹿混合基金重仓该股
天宇股份(300702.SZ):氯沙坦钾氢氯噻嗪片新规格获注册
智通财经 · 10-08
天宇股份(300702.SZ):氯沙坦钾氢氯噻嗪片新规格获注册
9月30日天宇股份涨13.99%,国泰金鹿混合基金重仓该股
证券之星 · 09-30
9月30日天宇股份涨13.99%,国泰金鹿混合基金重仓该股
天宇股份最新公告:全资子公司获西格列汀二甲双胍片药品注册证书
证券之星 · 09-25
天宇股份最新公告:全资子公司获西格列汀二甲双胍片药品注册证书
天宇股份(300702)9月24日主力资金净买入16.60万元
证券之星 · 09-24
天宇股份(300702)9月24日主力资金净买入16.60万元
天宇股份(300702)9月19日主力资金净卖出488.75万元
证券之星 · 09-19
天宇股份(300702)9月19日主力资金净卖出488.75万元
天宇股份(300702)股东屠勇军质押1250万股,占总股本3.59%
证券之星 · 09-13
天宇股份(300702)股东屠勇军质押1250万股,占总股本3.59%
天宇股份最新公告:全资子公司尼可地尔片收《药品注册证书》
证券之星 · 09-04
天宇股份最新公告:全资子公司尼可地尔片收《药品注册证书》
天宇股份(300702.SZ):尼可地尔片取得药品注册证书
智通财经 · 09-04
天宇股份(300702.SZ):尼可地尔片取得药品注册证书
天宇股份:8月29日召开业绩说明会,国泰基金管理有限公司、国泰君安等多家机构参与
证券之星 · 08-30
天宇股份:8月29日召开业绩说明会,国泰基金管理有限公司、国泰君安等多家机构参与
8月29日天宇股份涨5.12%,国泰金鹿混合基金重仓该股
证券之星 · 08-29
8月29日天宇股份涨5.12%,国泰金鹿混合基金重仓该股
合成生物概念盘中拉升,天宇股份涨2.02%
市场透视 · 08-29
合成生物概念盘中拉升,天宇股份涨2.02%
天宇股份(300702.SZ)发上半年业绩,净利润5321.52万元,同比减少21.87%
智通财经 · 08-28
天宇股份(300702.SZ)发上半年业绩,净利润5321.52万元,同比减少21.87%
天宇股份(300702)8月23日主力资金净卖出32.21万元
证券之星 · 08-23
天宇股份(300702)8月23日主力资金净卖出32.21万元
天宇股份(300702)8月19日主力资金净卖出197.74万元
证券之星 · 08-19
天宇股份(300702)8月19日主力资金净卖出197.74万元
天宇股份最新公告:拟1000万元参投扬州佰诺泽维创业投资合伙企业
证券之星 · 08-14
天宇股份最新公告:拟1000万元参投扬州佰诺泽维创业投资合伙企业
加载更多
公司概况
公司名称:
浙江天宇药业股份有限公司
所属行业:
医药制造业
上市日期:
2017-09-19
主营业务:
浙江天宇药业股份有限公司主营业务为化学原料药及中间体的研发、生产和销售。公司产品主要包括抗高血压药物原料药及中间体、抗哮喘药物原料药及中间体、抗病毒药物中间体等。公司目前已形成了以沙坦类药物原料药及中间体产品为主,抗病毒药物中间体及CMO业务多元发展的业务格局,是全球规模最大、品种最为齐全的沙坦类抗高血压药物原料药及中间体生产企业之一。
发行价格:
22.41
{"stockData":{"symbol":"300702","market":"SZ","secType":"STK","nameCN":"天宇股份","latestPrice":16.9,"timestamp":1731633900000,"preClose":16.98,"halted":0,"volume":4400,"delay":0,"floatShares":211000000,"shares":348000000,"eps":0.1256,"marketStatus":"等待开盘","marketStatusCode":7,"change":-0.08,"latestTime":"11-15 09:30:00","open":16.9,"high":16.9,"low":16.9,"amount":74400,"amplitude":0,"askPrice":16.9,"askSize":2,"bidPrice":16.88,"bidSize":2,"shortable":0,"etf":0,"ttmEps":0.1256,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1731634200000},"adr":0,"adjPreClose":16.98,"symbolType":"stock","openAndCloseTimeList":[[1731634200000,1731641400000],[1731646800000,1731654000000]],"highLimit":18.68,"lowLimit":15.28,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":347977159,"pbRate":1.67,"roa":"--","roe":"2.43%","epsLYR":0.08,"committee":-0.926063,"marketValue":5881000000,"floatMarketCap":3569000000,"peRate":134.554145,"changeRate":-0.0047,"turnoverRate":0,"status":1},"requestUrl":"/m/hq/s/300702","defaultTab":"news","newsList":[{"id":"2479292455","title":"天宇股份:10月29日接受机构调研,上海银叶投资有限公司、永赢基金管理有限公司等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2479292455","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479292455?lang=zh_cn&edition=full","pubTime":"2024-10-30 09:47","pubTimestamp":1730252834,"startTime":"0","endTime":"0","summary":"天宇股份主营业务:化学原料药及中间体的研发、注册、生产和销售。该股最近90天内共有4家机构给出评级,买入评级1家,增持评级3家;过去90天内机构目标均价为23.0。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000012004.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"gpt_icon":0},{"id":"2479740432","title":"图解天宇股份三季报:第三季度单季净利润同比增4570.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479740432","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479740432?lang=zh_cn&edition=full","pubTime":"2024-10-29 01:17","pubTimestamp":1730135877,"startTime":"0","endTime":"0","summary":"证券之星消息,天宇股份2024年三季报显示,公司主营收入19.32亿元,同比上升3.61%;归母净利润8511.41万元,同比上升23.72%;扣非净利润9129.87万元,同比下降30.67%;其中2024年第三季度,公司单季度主营收入6.67亿元,同比上升28.59%;单季度归母净利润3189.89万元,同比上升4570.27%;单季度扣非净利润2853.46万元,同比上升51.32%;负债率45.02%,投资收益-3991.98万元,财务费用1855.66万元,毛利率35.47%。财报数据概要请见下图:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900000593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702"],"gpt_icon":0},{"id":"2478980085","title":"天宇股份(300702)股东林洁质押160万股,占总股本0.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478980085","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478980085?lang=zh_cn&edition=full","pubTime":"2024-10-25 21:21","pubTimestamp":1729862464,"startTime":"0","endTime":"0","summary":"证券之星消息,天宇股份10月25日公开信息显示,股东林洁向广发证券股份有限公司合计质押160.0万股,占总股本0.46%。质押详情见下表:截止本公告日,股东林洁已累计质押股份3322.0万股,占其持股总数的27.22%,股东屠勇军已累计质押股份2450.0万股,占其持股总数的42.9%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102500044428.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2478607423","title":"天宇股份(300702.SZ):奥特康唑原料药通过CDE审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2478607423","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478607423?lang=zh_cn&edition=full","pubTime":"2024-10-25 18:45","pubTimestamp":1729853156,"startTime":"0","endTime":"0","summary":"智通财经APP讯,天宇股份(300702.SZ)公告,公司奥特康唑原料药于近日通过国家药品监督管理局药品审评中心(简称“CDE”)审评。奥特康唑可用于重度外阴阴道假丝酵母菌病的治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1200039.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300702","BK4017","BK0239","CDE"],"gpt_icon":0},{"id":"2473981449","title":"10月8日天宇股份涨9.09%,国泰金鹿混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2473981449","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473981449?lang=zh_cn&edition=full","pubTime":"2024-10-08 17:47","pubTimestamp":1728380836,"startTime":"0","endTime":"0","summary":"证券之星消息,10月8日天宇股份涨9.09%,收盘报19.2元,换手率6.27%,成交量13.24万手,成交额2.51亿元。根据2024基金半年报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为国泰金鹿混合。国泰金鹿混合目前规模为1.16亿元,最新净值1.9134,较上一交易日上涨9.17%,近一年下跌5.83%。国泰金鹿混合的前十大重仓股如下:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024100800026848.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"gpt_icon":0},{"id":"2473123624","title":"天宇股份(300702.SZ):氯沙坦钾氢氯噻嗪片新规格获注册","url":"https://stock-news.laohu8.com/highlight/detail?id=2473123624","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473123624?lang=zh_cn&edition=full","pubTime":"2024-10-08 16:10","pubTimestamp":1728375019,"startTime":"0","endTime":"0","summary":"智通财经APP讯,天宇股份(300702.SZ)公告,公司全资子公司浙江诺得药业有限公司(简称“诺得药业”)于近日收到国家药品监督管理局核准签发的关于氯沙坦钾氢氯噻嗪片新规格的《药品注册证书》,该药品用于治疗高血压,适用于联合用药治疗的患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1190924.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300702","BK0239"],"gpt_icon":0},{"id":"2471870475","title":"9月30日天宇股份涨13.99%,国泰金鹿混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2471870475","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471870475?lang=zh_cn&edition=full","pubTime":"2024-09-30 18:35","pubTimestamp":1727692544,"startTime":"0","endTime":"0","summary":"证券之星消息,9月30日天宇股份涨13.99%创60日新高,收盘报17.6元,换手率5.7%,成交量12.03万手,成交额2.01亿元。根据2024基金半年报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为国泰金鹿混合。国泰金鹿混合目前规模为1.16亿元,最新净值1.7526,较上一交易日上涨4.17%,近一年下跌13.48%。国泰金鹿混合的前十大重仓股如下:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024093000033023.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"gpt_icon":0},{"id":"2470232316","title":"天宇股份最新公告:全资子公司获西格列汀二甲双胍片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2470232316","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470232316?lang=zh_cn&edition=full","pubTime":"2024-09-25 18:29","pubTimestamp":1727260191,"startTime":"0","endTime":"0","summary":"天宇股份公告,全资子公司诺得药业的西格列汀二甲双胍片获得国家药监局颁发的药品注册证书,可在境内生产销售。西格列汀二甲双胍片是一种降血糖药,用于2型糖尿病患者的联合治疗。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024092500028813.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2469458828","title":"天宇股份(300702)9月24日主力资金净买入16.60万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2469458828","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2469458828?lang=zh_cn&edition=full","pubTime":"2024-09-24 15:25","pubTimestamp":1727162719,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年9月24日收盘,天宇股份报收于13.8元,上涨0.44%,换手率1.8%,成交量3.79万手,成交额5242.85万元。9月24日的资金流向数据方面,主力资金净流入16.6万元,占总成交额0.32%,游资资金净流入166.07万元,占总成交额3.17%,散户资金净流出182.67万元,占总成交额3.48%。天宇股份主营业务:化学原料药及中间体的研发、注册、生产和销售。该股最近90天内共有4家机构给出评级,买入评级1家,增持评级3家;过去90天内机构目标均价为23.0。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024092400018248.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2468154937","title":"天宇股份(300702)9月19日主力资金净卖出488.75万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2468154937","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468154937?lang=zh_cn&edition=full","pubTime":"2024-09-19 15:24","pubTimestamp":1726730687,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年9月19日收盘,天宇股份报收于14.26元,下跌0.07%,换手率0.99%,成交量2.09万手,成交额2997.91万元。9月19日的资金流向数据方面,主力资金净流出488.75万元,占总成交额16.3%,游资资金净流出53.24万元,占总成交额1.78%,散户资金净流入541.99万元,占总成交额18.08%。天宇股份主营业务:化学原料药及中间体的研发、注册、生产和销售。该股最近90天内共有2家机构给出评级,买入评级1家,增持评级1家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024091900017710.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"gpt_icon":0},{"id":"2467245778","title":"天宇股份(300702)股东屠勇军质押1250万股,占总股本3.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2467245778","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467245778?lang=zh_cn&edition=full","pubTime":"2024-09-13 21:27","pubTimestamp":1726234078,"startTime":"0","endTime":"0","summary":"证券之星消息,天宇股份9月13日公开信息显示,股东屠勇军向西藏信托有限公司合计质押1250.0万股,占总股本3.59%。质押详情见下表:截止本公告日,股东林洁已累计质押股份3162.0万股,占其持股总数的25.91%,股东屠勇军已累计质押股份3300.0万股,占其持股总数的57.78%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024091300042806.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2464327916","title":"天宇股份最新公告:全资子公司尼可地尔片收《药品注册证书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2464327916","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464327916?lang=zh_cn&edition=full","pubTime":"2024-09-04 18:31","pubTimestamp":1725445900,"startTime":"0","endTime":"0","summary":"天宇股份公告,全资子公司诺得药业于近日收到国家药监局核准签发的关于尼可地尔片的《药品注册证书》。尼可地尔片用于治疗心绞痛。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024090400031779.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2464322388","title":"天宇股份(300702.SZ):尼可地尔片取得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2464322388","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464322388?lang=zh_cn&edition=full","pubTime":"2024-09-04 18:15","pubTimestamp":1725444949,"startTime":"0","endTime":"0","summary":"智通财经APP讯,天宇股份(300702.SZ)公告,公司子公司浙江诺得药业有限公司(简称“诺得药业”)于近日收到国家药品监督管理局核准签发的关于尼可地尔片的《药品注册证书》,尼可地尔片用于治疗心绞痛。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1179315.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300702","BK0239"],"gpt_icon":0},{"id":"2463752200","title":"天宇股份:8月29日召开业绩说明会,国泰基金管理有限公司、国泰君安等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2463752200","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463752200?lang=zh_cn&edition=full","pubTime":"2024-08-30 22:53","pubTimestamp":1725029596,"startTime":"0","endTime":"0","summary":"未来,随着订单增加及产能规模逐年上升,生产成本下降,非沙坦类产品毛利率有望提升。答:报告期内,公司沙坦类原料药销量 894 吨,较去年同期增长了 12.74%,收入基本持平。该股最近90天内共有1家机构给出评级,买入评级1家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024083000051743.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0276","BK0188","BK1564","BK1147","BK0012","BK0028","BK0184","BK0201","02611","601211","300702","BK0239"],"gpt_icon":0},{"id":"2463001884","title":"8月29日天宇股份涨5.12%,国泰金鹿混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2463001884","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463001884?lang=zh_cn&edition=full","pubTime":"2024-08-29 16:24","pubTimestamp":1724919895,"startTime":"0","endTime":"0","summary":"证券之星消息,8月29日天宇股份涨5.12%,收盘报14.59元,换手率1.52%,成交量3.2万手,成交额4621.72万元。根据2024基金半年报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为国泰金鹿混合。国泰金鹿混合目前规模为1.16亿元,最新净值1.546,较上一交易日下跌0.33%,近一年下跌23.9%。国泰金鹿混合的前十大重仓股如下:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082900027996.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"gpt_icon":0},{"id":"2463342958","title":"合成生物概念盘中拉升,天宇股份涨2.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2463342958","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463342958?lang=zh_cn&edition=full","pubTime":"2024-08-29 09:46","pubTimestamp":1724895960,"startTime":"0","endTime":"0","summary":"08月29日,合成生物概念盘中拉升,截至09点45分,合成生物概念整体指数上涨0.51%,报808.610点。从个股上来看,该概念的成分股中,天宇股份涨2.02%,安琪酵母、华润双鹤、亚香股份涨幅居前。从资金上来看,截止发稿,合成生物概念主力净流入为-257.96万,其中安琪酵母受到资金热捧,主力净流入794.66万;拉长时间线来看,该板块近20日主力资金净流入-35.23亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240829094600af978330&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240829094600af978330&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0028","BK0185","BK0239","BK0188","BK0175","300702","600298","BK0226"],"gpt_icon":0},{"id":"2462467455","title":"天宇股份(300702.SZ)发上半年业绩,净利润5321.52万元,同比减少21.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2462467455","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462467455?lang=zh_cn&edition=full","pubTime":"2024-08-28 23:09","pubTimestamp":1724857771,"startTime":"0","endTime":"0","summary":"智通财经APP讯,天宇股份(300702.SZ)发布2024年半年度报告,营业收入12.65亿元,同比减少6.01%。归属于上市公司股东的净利润5321.52万元,同比减少21.87%。归属于上市公司股东的扣除非经常性损益的净利润6276.4万元,同比减少44.37%。基本每股收益0.15元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1174138.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300702"],"gpt_icon":0},{"id":"2461558526","title":"天宇股份(300702)8月23日主力资金净卖出32.21万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2461558526","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461558526?lang=zh_cn&edition=full","pubTime":"2024-08-23 15:26","pubTimestamp":1724397998,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年8月23日收盘,天宇股份报收于14.31元,下跌4.28%,换手率1.0%,成交量2.11万手,成交额3038.82万元。近5日资金流向一览见下表:该股主要指标及行业内排名如下:天宇股份2024年一季报显示,公司主营收入6.89亿元,同比下降11.29%;归母净利润4051.73万元,同比下降59.58%;扣非净利润5251.51万元,同比下降42.72%;负债率43.31%,投资收益-2637.71万元,财务费用-265.13万元,毛利率35.33%。天宇股份主营业务:化学原料药及中间体的研发、注册、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082300021230.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2460093697","title":"天宇股份(300702)8月19日主力资金净卖出197.74万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2460093697","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460093697?lang=zh_cn&edition=full","pubTime":"2024-08-19 15:26","pubTimestamp":1724052397,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年8月19日收盘,天宇股份报收于15.76元,下跌3.13%,换手率0.73%,成交量1.55万手,成交额2475.96万元。近5日资金流向一览见下表:该股主要指标及行业内排名如下:天宇股份2024年一季报显示,公司主营收入6.89亿元,同比下降11.29%;归母净利润4051.73万元,同比下降59.58%;扣非净利润5251.51万元,同比下降42.72%;负债率43.31%,投资收益-2637.71万元,财务费用-265.13万元,毛利率35.33%。天宇股份主营业务:化学原料药及中间体的研发、注册、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081900013628.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2459124370","title":"天宇股份最新公告:拟1000万元参投扬州佰诺泽维创业投资合伙企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2459124370","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459124370?lang=zh_cn&edition=full","pubTime":"2024-08-14 19:19","pubTimestamp":1723634373,"startTime":"0","endTime":"0","summary":"天宇股份公告,公司与上海佰诺私募基金管理有限公司(简称“上海佰诺”)及其他有限合伙人签署了《扬州佰诺泽维创业投资合伙企业(有限合伙)合伙协议》,共同投资扬州佰诺泽维创业投资合伙企业(有限合伙)。公司作为有限合伙人以自有资金出资人民币1,000万元认缴扬州佰诺泽维的部分份额。上海佰诺为扬州佰诺泽维的基金管理人。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081400039549.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2017-09-19","address":"浙江省台州市黄岩区黄岩江口化工开发区","stockEarnings":[{"period":"1week","weight":-0.0236},{"period":"1month","weight":0.0726},{"period":"3month","weight":0.0436},{"period":"6month","weight":-0.1692},{"period":"1year","weight":-0.251},{"period":"ytd","weight":-0.2158}],"companyName":"浙江天宇药业股份有限公司","boardCode":"AI0027","perCapita":"13515股","boardName":"医药制造业","registeredCapital":"34797万元","compareEarnings":[{"period":"1week","weight":-0.0262},{"period":"1month","weight":0.0558},{"period":"3month","weight":0.1738},{"period":"6month","weight":0.0716},{"period":"1year","weight":0.0999},{"period":"ytd","weight":0.1361}],"survey":" 浙江天宇药业股份有限公司主营业务为化学原料药及中间体的研发、生产和销售。公司产品主要包括抗高血压药物原料药及中间体、抗哮喘药物原料药及中间体、抗病毒药物中间体等。公司目前已形成了以沙坦类药物原料药及中间体产品为主,抗病毒药物中间体及CMO业务多元发展的业务格局,是全球规模最大、品种最为齐全的沙坦类抗高血压药物原料药及中间体生产企业之一。","serverTime":1731633968441,"listedPrice":22.41,"stockholders":"15624人(较上一季度增加9.57%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"天宇股份(300702)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供天宇股份(300702)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"天宇股份,300702,天宇股份股票,天宇股份股票老虎,天宇股份股票老虎国际,天宇股份行情,天宇股份股票行情,天宇股份股价,天宇股份股市,天宇股份股票价格,天宇股份股票交易,天宇股份股票购买,天宇股份股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"天宇股份(300702)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供天宇股份(300702)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}